News items related to:
-
Civil Society Groups Unite to Monitor the 4th Round of Thailand-EU FTA Negotiation
Grave concerns over expensive medicines, the universal health coverage scheme at risk, unsafe second-hand medical devices, farmers’ increasing debts &...
-
MMA Partner VNP+ Opposes Patent Application Which Would Limit Access to Long-Acting Cabotegravir
Vietnam’s Network of People Living With HIV (VNP+), a Make Medicines Affordable (MMA) partner, is working to improve access to, and affordability...
-
Thai HIV Advocacy Group Challenges Gilead’s and Janssen’s Patent Extension Bid, Citing Evergreening Tactics
The Thai Network of People Living with HIV/AIDS (TNP+) filed an opposition to a patent application filed by the U.S.-based pharmaceutical giant...
-
Global South Leaders Condemn Gilead’s Restrictive License on HIV Prevention Breakthrough
Civil society organizations across the Global South are blasting the U.S.-based pharmaceutical company Gilead Sciences for its lenacapavir (LEN) voluntary...
-
Indonesian Advocates Challenge Big Pharma’s Patent of HIV Prevention and Treatment Lenacapavir
Indonesia AIDS Coalition (IAC), a community-based organization advocating on HIV-related issues, filed a post-grant opposition against the secondary (selection) patent...
-
Why the World Can’t Trust Pharmaceutical Companies to Ensure Global Access to Essential Medicines
ITPC Global’s reaction to Gilead’s voluntary licence on lenacapravir: Gilead’s announcement of their voluntary license for lenacapavir—a groundbreaking, long-acting HIV...
-
Patent Applications for HIV Prevention Drug Opposed in India: Vulnerable Group Seeks to Protect Generic Competition to Lower Prices of HIV Prevention Drug Lenacapavir
New Delhi, 18 September 2024 – The Indian Patent Office is set to hear the objections of Sankalp Rehabilitation Trust...
-
HIV Community-Based Organizations are Fighting Patent Monopolies on Lenacapavir
Despite the world’s efforts, there have been over a million new cases of HIV each year. Lenacapavir (LEN), a long-acting...
-
ITPC Sounds Alarm to Prevent Mpox Treatment Disparities as WHO Declares Global Health Emergency
July 15, 2024 — ITPC Global welcomes the World Health Organization’s (WHO) declaration of the current mpox upsurge as a Public...
-
Ending the Epidemic Could Cost Under $40 (per person, per year) – treatment activists say at AIDS2024
Munich, 23 July 2024 – Despite global efforts to end HIV and AIDS, the epidemic has been persistent. In 2022,...
-
Activists at AIDS2024 called on ViiV Healthcare to drop their case in Colombia against Compulsory License on Dolutegravir
On the 24th of July, hundreds of treatment advocates attending AIDS2024 in Munich protested against the companies with “Drop The...
-
TBPeople: fighting for affordable medicines in Georgia
